DK2819648T3 - Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat - Google Patents

Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat Download PDF

Info

Publication number
DK2819648T3
DK2819648T3 DK13707000.9T DK13707000T DK2819648T3 DK 2819648 T3 DK2819648 T3 DK 2819648T3 DK 13707000 T DK13707000 T DK 13707000T DK 2819648 T3 DK2819648 T3 DK 2819648T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
preparation containing
antiviral effective
dihydroquinazoline derivative
dihydroquinazoline
Prior art date
Application number
DK13707000.9T
Other languages
Danish (da)
English (en)
Inventor
Kerstin Paulus
Dominique Grunder
Wilfried Schwab
Hoogevest Peter Van
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2819648(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Application granted granted Critical
Publication of DK2819648T3 publication Critical patent/DK2819648T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK13707000.9T 2012-02-29 2013-02-28 Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat DK2819648T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Publications (1)

Publication Number Publication Date
DK2819648T3 true DK2819648T3 (da) 2019-08-26

Family

ID=47757622

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13707000.9T DK2819648T3 (da) 2012-02-29 2013-02-28 Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat
DK19176985.0T DK3556350T3 (da) 2012-02-29 2013-02-28 Farmaceutisk præparat indeholdende et antiviralt aktivt dihydroquinazolinderivat med s-konfiguration i 4-stillingen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19176985.0T DK3556350T3 (da) 2012-02-29 2013-02-28 Farmaceutisk præparat indeholdende et antiviralt aktivt dihydroquinazolinderivat med s-konfiguration i 4-stillingen

Country Status (37)

Country Link
US (1) US10603384B2 (enExample)
EP (3) EP2819648B1 (enExample)
JP (1) JP6387486B2 (enExample)
KR (1) KR102149561B1 (enExample)
CN (2) CN110433166A (enExample)
AU (1) AU2013224947B2 (enExample)
BR (1) BR112014020946B1 (enExample)
CA (1) CA2865203C (enExample)
CL (1) CL2014002306A1 (enExample)
CO (1) CO7061076A2 (enExample)
CY (1) CY1121910T1 (enExample)
DE (1) DE102012101680A1 (enExample)
DK (2) DK2819648T3 (enExample)
EA (1) EA026584B1 (enExample)
ES (2) ES2972133T3 (enExample)
FI (1) FI3556350T3 (enExample)
HR (2) HRP20240197T1 (enExample)
HU (2) HUE045949T2 (enExample)
IL (1) IL234363B (enExample)
IN (1) IN2014MN01892A (enExample)
LT (2) LT3556350T (enExample)
MA (1) MA35941B1 (enExample)
ME (1) ME03448B (enExample)
MX (1) MX369666B (enExample)
MY (1) MY172310A (enExample)
NZ (1) NZ628444A (enExample)
PH (1) PH12014501937B1 (enExample)
PL (2) PL2819648T3 (enExample)
PT (2) PT2819648T (enExample)
RS (2) RS59157B1 (enExample)
SG (1) SG11201405294XA (enExample)
SI (2) SI3556350T1 (enExample)
SM (2) SMT201900458T1 (enExample)
TN (1) TN2014000345A1 (enExample)
UA (1) UA111415C2 (enExample)
WO (1) WO2013127970A1 (enExample)
ZA (1) ZA201405949B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
MD4673C1 (ro) * 2013-06-19 2020-11-30 Aicuris Anti-Infective Cures Gmbh Letermovir amorf şi forme preparative farmaceutice solide ale acestuia pentru administrare orală
AU2017274722A1 (en) 2016-06-03 2019-01-17 Atreya Innovations Private Limited A device for the detection and reliable capturing of the pulse characteristics
PH12019502037B1 (en) * 2017-03-06 2024-06-05 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
DK3886798T3 (da) 2018-11-29 2026-04-20 Basilea Pharmaceutica Int Ag Allschwil Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf
UY39097A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39099A (es) * 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
UY40078A (es) 2021-12-21 2023-06-30 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin
EP4467126A4 (en) * 2022-02-23 2025-04-30 LG Chem, Ltd. Injectable formulation containing isoxazoline derivative and method for producing the same
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN119731157A (zh) * 2022-08-15 2025-03-28 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法
CN119015222B (zh) * 2024-08-28 2025-12-09 石家庄四药有限公司 一种来特莫韦注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度tcf製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
DE60010448T2 (de) * 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
SI1689724T1 (sl) * 2003-11-25 2012-04-30 Novartis Ag Spojine kinazolinona kot sredstva proti raku
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
SMT202400068T1 (it) 2024-03-13
EA201400963A1 (ru) 2015-02-27
EP2819648A1 (de) 2015-01-07
EP2819648B1 (de) 2019-05-29
KR102149561B1 (ko) 2020-08-31
ZA201405949B (en) 2021-07-28
HRP20191369T1 (hr) 2019-11-01
HRP20240197T1 (hr) 2024-04-26
ES2741698T3 (es) 2020-02-12
CL2014002306A1 (es) 2014-11-28
RS59157B1 (sr) 2019-10-31
LT2819648T (lt) 2019-09-10
US20150133461A1 (en) 2015-05-14
CY1121910T1 (el) 2020-10-14
EP3556350B1 (de) 2024-01-10
HK1205462A1 (en) 2015-12-18
JP6387486B2 (ja) 2018-09-12
MA35941B1 (fr) 2014-12-01
MX2014010364A (es) 2014-12-05
KR20140130683A (ko) 2014-11-11
HUE045949T2 (hu) 2020-01-28
LT3556350T (lt) 2024-02-26
PH12014501937B1 (en) 2022-07-15
DK3556350T3 (da) 2024-02-12
EP3556350A1 (de) 2019-10-23
IL234363B (en) 2020-04-30
ES2972133T3 (es) 2024-06-11
BR112014020946A2 (enExample) 2017-06-20
PL3556350T3 (pl) 2024-05-06
NZ628444A (en) 2016-07-29
PL2819648T3 (pl) 2019-10-31
MX369666B (es) 2019-11-14
CN110433166A (zh) 2019-11-12
EA026584B1 (ru) 2017-04-28
TN2014000345A1 (en) 2015-12-21
DE102012101680A1 (de) 2013-08-29
PH12014501937A1 (en) 2014-11-24
SI3556350T1 (sl) 2024-03-29
MY172310A (en) 2019-11-21
CO7061076A2 (es) 2014-09-19
HUE065553T2 (hu) 2024-06-28
IN2014MN01892A (enExample) 2015-07-10
AU2013224947B2 (en) 2017-06-29
ME03448B (me) 2020-01-20
PT2819648T (pt) 2019-09-05
SG11201405294XA (en) 2014-11-27
CN104144678A (zh) 2014-11-12
BR112014020946B1 (pt) 2022-04-05
FI3556350T3 (fi) 2024-02-14
WO2013127970A1 (de) 2013-09-06
CA2865203A1 (en) 2013-09-06
SMT201900458T1 (it) 2019-11-13
CA2865203C (en) 2019-11-05
SI2819648T1 (sl) 2019-10-30
RS65137B1 (sr) 2024-02-29
US10603384B2 (en) 2020-03-31
AU2013224947A1 (en) 2014-09-18
PT3556350T (pt) 2024-02-15
JP2015508801A (ja) 2015-03-23
UA111415C2 (uk) 2016-04-25
EP4328218A3 (de) 2024-04-10
EP4328218A2 (de) 2024-02-28

Similar Documents

Publication Publication Date Title
DK2812000T3 (da) Flerlaget nikotinholdig farmaceutisk sammensætning
PL3067358T3 (pl) Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
HUE056014T2 (hu) Lipidek gyógyszerszállító készítményekhez
HUE045949T2 (hu) Vírusellenes dihidrokinazolin-származékot tartalmazó gyógyászati készítmény
PT2854768T (pt) Composições farmacêuticas de pemetrexed
EP2832453A4 (en) ATOMIZERS
DK3444281T3 (da) Forbedrede peptidlægemidler
IL230838A0 (en) Pharmaceutical compositions
CO6940426A2 (es) Formulaciones farmacéuticas
DK2502622T3 (da) Farmaceutisk formulering omfattende inositol
DK2897594T3 (da) Farmaceutisk sammensætning
CL2014003283A1 (es) Formulación farmacéutica.
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
EP2838488A4 (en) DRUGS DONORS
BR112014015885A8 (pt) preparação farmacêutica
EP2883547A4 (en) MEDICINE
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
DK2854765T3 (da) Farmaceutisk pemetrexed-opløsning
BR302012003979S1 (pt) Configuração aplicada em fármaco
DK2908836T3 (da) Farmaceutisk formulering indeholdende curcuma
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
FI20126169A7 (fi) Lääkejakelujärjestelmä
BR112014021433A2 (pt) formulações farmacêuticas
PL2922571T3 (pl) Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran